The global aortic valve market is forecasted to attain revenue of $13.6 billion by 2025, according to P&S Market Research.The market is mainly driven by increasing prevalence of valvular diseases, increasing demand for minimally invasive surgeries (MISs), rise in number of clinical trials for heart valves, and introduction of advanced implants.
The different types of valves available in the aortic valve market are transcatheter valves, sutureless valves and others. Among these, transcatheter valves attained the largest share of 58.8% in the market, in 2017. This leading position of the category is attributed to increasing initiatives for research activities for developing transcatheter valves and increasing number of clinical trials to study transcatheter valves. For instance, In December 2017, Edwards Lifesciences Corporation announced new data demonstrating the economic advantages of the company’s SAPIEN 3 transcatheter aortic valve.
The key end user in the aortic valve market includes hospitals, and others. Among these, hospitals registered the larger share, of 76.3%, in the market in 2017, owing to increasing number of patient population with valvular diseases in the hospitals.
Request to Get the Sample Pages at: https://www.psmarketresearch.com/market-analysis/aortic-valve-market/report-sample
During the forecast period, the aortic valve industry is expected to witness the fastest growth in demand in Asia-Pacific (APAC), at a CAGR of 13.0%, owing to the presence of large number of patient population with cardiovascular diseases, rising number of aortic valve replacement surgeries, growing medical tourism, and continuously improving healthcare infrastructure.
Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=aortic-valve-market
Globally, key players in the aortic valve industry are seeking for approvals to launch new products in the market. For instance, in February 2018, Edwards Lifesciences Corporation received CE Mark for its self-expanding CENTERA valve for severe, symptomatic aortic stenosis patients at high risk of open surgery. In March 2018, LivaNova Plc received CE Mark approval for its Bicarbon aortic valves for use with low-dose anticoagulant therapy. This expanded indication of the company’s Bicarbon family of mechanical valves is based on evidence and results from the LOWERING-IT trial.
Some of the other key players operating in the aortic valve market are Medtronic plc and Boston Scientific Corporation.
About P&S Intelligence
P&S Intelligence, a brand of P&S Market Research, is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.
Toll-free: +1-888-778-7886 (USA/Canada)